Enzon Pharmaceuticals Announces 1-for-100 Reverse Stock Split Effective Today, Paving Way for Merger
ENZN has more than doubled off its 52-week low of $0.015 on light trading volume (0.3× avg).
Summary
Enzon Pharmaceuticals announced its 1-for-100 reverse stock split will become effective today, a mandatory step for its pending merger with Viskase.
Key Events · Corporate Governance and Compliance · ENZN
-
Reverse Stock Split Effective
Enzon Pharmaceuticals announced its 1-for-100 reverse stock split will become effective on March 24, 2026, at 4:30 p.m. Eastern Time.
-
Trading on Split-Adjusted Basis
Common Stock is expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026.
-
Merger Requirement Fulfilled
The reverse stock split was a required step for the consummation of the previously disclosed transformational merger with Viskase, as noted in the company's recent 10-K filing.
Analysis · ENZN · Life Sciences
Enzon Pharmaceuticals announced the effective date for its previously disclosed 1-for-100 reverse stock split. This significant corporate action, which will see common stock trade on a split-adjusted basis starting March 25, 2026, is a critical step required for the consummation of the company's transformational merger with Viskase. While necessary for the merger, reverse stock splits are generally viewed negatively as they often indicate a company's struggle to maintain a viable share price.
At the time of this filing, ENZN was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.02 to $0.13. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.